Connect your AI

Denali Therapeutics Inc. DNLI Debt-to-assets

Debt-to-assets at other companies

Eli LillyLLY

0.4×-0.1×

Regeneron PharmaceuticalsREGN

0.1×0.0×

Ultragenyx PharmaceuticalRARE

0×0.0×

Viking TherapeuticsVKTX

0×0.0×

uniQureQURE

0.1×0.0×

BiogenBIIB

0.2×0.0×

Other financials

Income statement

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

Market cap$3.93B+54.2%

Profitability

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

total debt/total assets=0×

Based on the most recent quarter.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Denali Therapeutics Inc.'s debt-to-assets?: Denali Therapeutics Inc. (DNLI) reported debt-to-assets of 0× in Q1 2026.
How has Denali Therapeutics Inc.'s debt-to-assets changed year-over-year?: Denali Therapeutics Inc.'s debt-to-assets decreased by 22.2% year-over-year, from 0× to 0×.
What is the long-term trend for Denali Therapeutics Inc.'s debt-to-assets?: Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s debt-to-assets has grown at a -2.9% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?: Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.